The Emergence of Novel Biomarkers and Model Systems for ALS: Rita Sattler, MD, MSc
February 19th 2024The professor in the Department of Translational Neuroscience at Barrow Neurological Institute provided comments on her session track at the upcoming 2024 MDA conference and some of the recent advancements in ALS research. [WATCH TIME: 4 minutes]
Susceptibility-Weighted Imaging Features Show Promise in Distinguishing AQP4-Negative-NMOSD From MS
February 17th 2024A recent study highlighted the potential of susceptibility-weighted image features as imaging biomarkers to differentiate patients with multiple sclerosis from those with neuromyelitis optica spectrum disorder.
Understanding Patient Subgroups Who Benefit From Tenecteplase After 4.5 Hours: Gregory W. Albers, MD
February 16th 2024The professor of neurology and director of the Stanford Stroke Center provided commentary on clinical implications of findings from the TIMELESS trial assessing tenecteplase initiated in the late window after stroke onset. [WATCH TIME: 4 minutes]
Using a Portable Low Field MRI for Timely Diagnoses of Stroke: Annabel Sorby-Adams, PhD
February 15th 2024The postdoctoral research fellow in neurology at Harvard Medical School talked about the potential of a portable low field MRI device to provide timely and cost-effective diagnoses for stroke. [WATCH TIME: 4 minutes]
Laquinimod Significantly Reduces Caudate Volume in Phase 2 LEGATO-HD Study
February 15th 2024Considering the favorable safety profile and acknowledging the unmet therapeutic needs in Huntington disease, further investigation of laquinimod or other immune-modulating therapeutics might be warranted.
Assisted Reproductive Technologies Increase Risk of In-Hospital Stroke in Pregnant Women
February 14th 2024In a recent study presented at ISC 2024, results revealed that patients who used assisted reproductive technologies therapy during hospitalization for delivery had a higher risk of stroke than those who did not use such therapies.
European Commission Approves Omaveloxolone as First Therapy for Friedreich Ataxia
February 14th 2024Omaveloxolone is an oral, once-daily medication indicated for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older in both the United States and the European Union.
A Caregiver’s Perspective on Embracing Love for Patients With Alzheimer Disease
February 14th 2024Eleonora Tornatore-Mikesh, chief executive officer of CaringKind, The Heart of Alzheimer's Caregiving, and an anonymous caregiver, spoke about their perspective with caring for a loved one who has been diagnosed with Alzheimer disease.
The Evolving Landscape of Treatments for Multiple Sclerosis in 2024: Enrique Alvarez, MD, PhD
February 14th 2024The associate professor of neurology at the University of Colorado School of Medicine talked about promising developments in multiple sclerosis treatment strategies for 2024. [WATCH TIME: 6 minutes]